| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104
C4b and C3b deposited on host cells undergo limited proteolytic cleavage by regulatory proteins. Membrane cofactor protein (MCP; CD46), factor H, and C4b binding protein mediate this reaction, known as cofactor activity, that also requires the plasma serine protease factor I. To explore the roles of the fluid phase regulators vs those expressed on host cells, a model system was used examining complement fragments deposited on cells transfected with human MCP as assessed by FACS and Western blotting. Following incubation with Ab and complement on MCP+ cells, C4b was progressively cleaved over the first hour to C4d and C4c. There was no detectable cleavage of C4b on MCP- cells, indicating that MCP (and not C4BP in the serum) primarily mediates this cofactor activity. C3b deposition was not blocked on MCP+ cells because classical pathway activation occurred before substantial C4b cleavage. Cleavage, though, of deposited C3b was rapid (<5 min) and iC3b was the dominant fragment on MCP- and MCP+ cells. Studies using a function-blocking mAb further established factor H as the responsible cofactor. If the level of Ab sensitization was reduced 8-fold or if Mg2+-EGTA was used to block the classical pathway, MCP efficiently inhibited C3b deposition mediated by the alternative pathway. Thus, for the classical pathway, MCP is the cofactor for C4b cleavage and factor H for C3b cleavage. However, if the alternative pathway mediates C3b deposition, then MCP’s cofactor activity is sufficient to restrict complement activation.
This article has been cited by other articles:
|
|
 |
|
  M. K. Liszewski, M. K. Leung, R. Hauhart, C. J. Fang, P. Bertram, and J. P. Atkinson Smallpox Inhibitor of Complement Enzymes (SPICE): Dissecting Functional Sites and Abrogating Activity J. Immunol., September 1, 2009; 183(5): 3150 - 3159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Johnson, K. Grant, and G. D. Parks The Paramyxoviruses Simian Virus 5 and Mumps Virus Recruit Host Cell CD46 To Evade Complement-Mediated Neutralization J. Virol., August 1, 2009; 83(15): 7602 - 7611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Delvaeye, M. Noris, A. De Vriese, C. T. Esmon, N. L. Esmon, G. Ferrell, J. Del-Favero, S. Plaisance, B. Claes, D. Lambrechts, et al. Thrombomodulin Mutations in Atypical Hemolytic-Uremic Syndrome N. Engl. J. Med., July 23, 2009; 361(4): 345 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. D. Krishna, M. Rangappa, and V. Satchidanandam Virus-Specific Cytolytic Antibodies to Nonstructural Protein 1 of Japanese Encephalitis Virus Effect Reduction of Virus Output from Infected Cells J. Virol., May 15, 2009; 83(10): 4766 - 4777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Liszewski, P. Bertram, M. K. Leung, R. Hauhart, L. Zhang, and J. P. Atkinson Smallpox Inhibitor of Complement Enzymes (SPICE): Regulation of Complement Activation on Cells and Mechanism of Its Cellular Attachment J. Immunol., September 15, 2008; 181(6): 4199 - 4207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ben Nasr and G. R. Klimpel Subversion of complement activation at the bacterial surface promotes serum resistance and opsonophagocytosis of Francisella tularensis J. Leukoc. Biol., July 1, 2008; 84(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fang, V. Fremeaux-Bacchi, M. K. Liszewski, G. Pianetti, M. Noris, T. H. J. Goodship, and J. P. Atkinson Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome Blood, January 15, 2008; 111(2): 624 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Banda, K. Takahashi, A. K. Wood, V. M. Holers, and W. P. Arend Pathogenic Complement Activation in Collagen Antibody- Induced Arthritis in Mice Requires Amplification by the Alternative Pathway J. Immunol., September 15, 2007; 179(6): 4101 - 4109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Li, D. J. Allendorf, R. Hansen, J. Marroquin, D. E. Cramer, C. L. Harris, and J. Yan Combined Yeast {beta}-Glucan and Antitumor Monoclonal Antibody Therapy Requires C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay-Accelerating Factor CD55 Cancer Res., August 1, 2007; 67(15): 7421 - 7430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Buettner, M. Huang, T. Gritsko, J. Karras, S. Enkemann, T. Mesa, S. Nam, H. Yu, and R. Jove Activated Signal Transducers and Activators of Transcription 3 Signaling Induces CD46 Expression and Protects Human Cancer Cells from Complement-Dependent Cytotoxicity Mol. Cancer Res., August 1, 2007; 5(8): 823 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heinen, M. Jozsi, A. Hartmann, M. Noris, G. Remuzzi, C. Skerka, and P. F. Zipfel Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells J. Am. Soc. Nephrol., February 1, 2007; 18(2): 506 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Chung, M. K. Liszewski, G. Nybakken, A. E. Davis, R. R. Townsend, D. H. Fremont, J. P. Atkinson, and M. S. Diamond From the Cover: West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H PNAS, December 12, 2006; 103(50): 19111 - 19116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Krey, A. Himmelreich, M. Heimann, C. Menge, H.-J. Thiel, K. Maurer, and T. Rumenapf Function of Bovine CD46 as a Cellular Receptor for Bovine Viral Diarrhea Virus Is Determined by Complement Control Protein 1. J. Virol., April 1, 2006; 80(8): 3912 - 3922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, X.-M. Xu, C. B. Underhill, S. Yang, L. Wang, Y. Chen, S. Hong, K. Creswell, and L. Zhang Tachyplesin Activates the Classic Complement Pathway to Kill Tumor Cells Cancer Res., June 1, 2005; 65(11): 4614 - 4622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Noris and G. Remuzzi Hemolytic Uremic Syndrome J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1035 - 1050. [Full Text] [PDF]
|
|
|
|
 |
|
 V Fremeaux-Bacchi, M-A Dragon-Durey, J Blouin, C Vigneau, D Kuypers, B Boudailliez, C Loirat, E Rondeau, and W H Fridman Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome J. Med. Genet., June 1, 2004; 41(6): e84 - e84. [Full Text] [PDF]
|
|
|
|
|
|
K. Maurer, T. Krey, V. Moennig, H.-J. Thiel, and T. Rumenapf CD46 Is a Cellular Receptor for Bovine Viral Diarrhea Virus J. Virol., February 15, 2004; 78(4): 1792 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Rezende, R. E. Simmonds, and D. A. Lane Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex Blood, February 15, 2004; 103(4): 1192 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Richards, E. J. Kemp, M. K. Liszewski, J. A. Goodship, A. K. Lampe, R. Decorte, M. H. Muslumanogglu, S. Kavukcu, G. Filler, Y. Pirson, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome PNAS, October 28, 2003; 100(22): 12966 - 12971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Platt C4d and the Fate of Organ Allografts J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2417 - 2419. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
